KR101881714B1 - 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법 - Google Patents

항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법 Download PDF

Info

Publication number
KR101881714B1
KR101881714B1 KR1020177020281A KR20177020281A KR101881714B1 KR 101881714 B1 KR101881714 B1 KR 101881714B1 KR 1020177020281 A KR1020177020281 A KR 1020177020281A KR 20177020281 A KR20177020281 A KR 20177020281A KR 101881714 B1 KR101881714 B1 KR 101881714B1
Authority
KR
South Korea
Prior art keywords
labeled
delete delete
drug
tnf
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177020281A
Other languages
English (en)
Korean (ko)
Other versions
KR20170088437A (ko
Inventor
샬렛 싱
슈이 롱 왕
린다 오르문드
Original Assignee
네스텍 소시에테아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 네스텍 소시에테아노님 filed Critical 네스텍 소시에테아노님
Publication of KR20170088437A publication Critical patent/KR20170088437A/ko
Application granted granted Critical
Publication of KR101881714B1 publication Critical patent/KR101881714B1/ko
Assigned to 소시에떼 데 프로듀이 네슬레 소시에떼아노님 reassignment 소시에떼 데 프로듀이 네슬레 소시에떼아노님 권리의 전부이전등록 Assignors: 네스텍 소시에테아노님
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
KR1020177020281A 2009-10-26 2010-10-26 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법 Expired - Fee Related KR101881714B1 (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US25504809P 2009-10-26 2009-10-26
US61/255,048 2009-10-26
US26287709P 2009-11-19 2009-11-19
US61/262,877 2009-11-19
US32463510P 2010-04-15 2010-04-15
US61/324,635 2010-04-15
US34556710P 2010-05-17 2010-05-17
US61/345,567 2010-05-17
US35126910P 2010-06-03 2010-06-03
US61/351,269 2010-06-03
US38967210P 2010-10-04 2010-10-04
US61/389,672 2010-10-04
US39358110P 2010-10-15 2010-10-15
US61/393,581 2010-10-15
PCT/US2010/054125 WO2011056590A1 (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127013748A Division KR101761541B1 (ko) 2009-10-26 2010-10-26 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법

Publications (2)

Publication Number Publication Date
KR20170088437A KR20170088437A (ko) 2017-08-01
KR101881714B1 true KR101881714B1 (ko) 2018-07-24

Family

ID=43618083

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177020281A Expired - Fee Related KR101881714B1 (ko) 2009-10-26 2010-10-26 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법
KR1020127013748A Expired - Fee Related KR101761541B1 (ko) 2009-10-26 2010-10-26 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127013748A Expired - Fee Related KR101761541B1 (ko) 2009-10-26 2010-10-26 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법

Country Status (15)

Country Link
US (5) US8574855B2 (https=)
EP (1) EP2494352B1 (https=)
JP (3) JP5697677B2 (https=)
KR (2) KR101881714B1 (https=)
CN (2) CN102695955B (https=)
AU (4) AU2010315547C1 (https=)
BR (1) BR112012009855A2 (https=)
CA (2) CA2778454C (https=)
ES (1) ES2796530T3 (https=)
IL (2) IL219315B (https=)
MX (2) MX2012004877A (https=)
NZ (3) NZ706187A (https=)
RU (2) RU2015148676A (https=)
WO (1) WO2011056590A1 (https=)
ZA (2) ZA201203717B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3225625A1 (en) 2002-09-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Protein purification method
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5697677B2 (ja) 2009-10-26 2015-04-08 ネステク ソシエテ アノニム 抗ｔｎｆ薬及び自己抗体の検出用アッセイ
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
CA2827609A1 (en) * 2011-02-17 2012-11-15 Nestec S.A. Assays for detecting autoantibodies to anti-tnf.alpha. drugs
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
KR20140047628A (ko) * 2011-07-06 2014-04-22 네스텍 소시에테아노님 Ｔｎｆ알파로의 생물학적 치료요법에 대한 중화 자가항체의 검출을 위한 검정
EP2786156A2 (en) * 2011-11-30 2014-10-08 AbbVie Deutschland GmbH & Co KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
KR102084805B1 (ko) * 2012-03-08 2020-03-04 에프. 호프만-라 로슈 아게 순환 면역 복합체의 특성화를 위한 다중 크로마토그래피-면역분석 방법
US20130295685A1 (en) * 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US10132736B2 (en) 2012-05-24 2018-11-20 Abbvie Inc. Methods for inspection of protein particles in a liquid beneficial agent
WO2014046474A2 (ko) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
KR101501375B1 (ko) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
EP2904405B1 (en) 2012-10-05 2017-05-31 Nestec S.A. Methods for predicting and monitoring mucosal healing
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
WO2014184768A1 (en) * 2013-05-16 2014-11-20 University Of Pretoria A method of diagnosing tuberculosis
WO2015083087A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Methods for predicting post-operative recurrence of crohn's disease
CA2932569A1 (en) 2013-12-03 2015-06-11 Societe Des Produits Nestle S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
MX2017004816A (es) 2014-10-20 2017-08-02 Nestec Sa Métodos para predecir resultados clínicos en sujetos afectados con colitis ulcerosa.
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
HK1244881A1 (zh) 2014-12-02 2018-08-17 Société des Produits Nestlé S.A. 建立维多珠单坑给药方案以治疗患有易激惹肠病的患者的方法
CN107250798A (zh) 2014-12-05 2017-10-13 雀巢产品技术援助有限公司 用于检测患者样品中的生物制品的间接均相迁移率变动试验
CN107110853A (zh) * 2015-01-09 2017-08-29 阿通诺米斯公司 确定TNFα抑制药及其相应抗药抗体的量的通用测定法
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
ES2716900T3 (es) 2015-11-06 2019-06-17 Promise Advanced Proteomics Un método para cuantificar anticuerpos anti-TNF
EP3165922B1 (en) 2015-11-06 2020-06-17 Promise Proteomics A method for quantifying therapeutic antibodies
WO2017201142A1 (en) * 2016-05-17 2017-11-23 Memorial Sloan Kettering Cancer Center Treatment of lung adenocarcinoma
WO2018007327A1 (en) * 2016-07-08 2018-01-11 Atonomics A/S A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples
KR20200069333A (ko) 2017-10-10 2020-06-16 프로메테우스 바이오사이언시즈, 인크. 베돌리주맙 치료를 모니터링하는 방법
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
EP3781941B1 (en) * 2018-04-20 2026-01-14 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for producing anti-tnf antibody compositions
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
US20230035363A1 (en) * 2019-03-04 2023-02-02 Amgen Inc. In vivo reversibility of high molecular weight species
KR102562006B1 (ko) 2020-11-09 2023-08-02 바디텍메드(주) 항tnf-알파 약물 모니터링을 위한 신속 검출 키트
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4459359A (en) 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4857456A (en) 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
US5094740A (en) 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5582998A (en) 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
JPH0566222A (ja) 1991-09-09 1993-03-19 Tosoh Corp 物質の分析方法
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
DE69426223T2 (de) 1993-09-07 2001-05-23 Wako Pure Chemical Industries, Ltd. Verfahren und Reagenz zur Messung der Komplementaktivität
JPH07110331A (ja) * 1993-09-07 1995-04-25 Wako Pure Chem Ind Ltd ヒト補体価測定方法及びヒト補体価測定用試薬組成物
JPH07140144A (ja) 1993-11-19 1995-06-02 S R L:Kk アレルゲン特異的ＩｇＥ抗体の測定方法および抗原抗体複合体の測定方法
EP0796280B1 (en) * 1994-12-28 2003-03-26 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
AU727500B2 (en) 1996-08-12 2000-12-14 Sekisui Kagaku Kogyo Kabushiki Kaisha Container for measurement of cell functions, kit for measurement of cell functions and method for measuring cell functions
JP3718435B2 (ja) * 1996-08-12 2005-11-24 積水化学工業株式会社 細胞機能測定用容器及び細胞機能測定方法
US6391622B1 (en) 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
CA2348698C (en) * 1998-10-31 2012-01-03 Syed V. S. Kashmiri Variants of humanized anti-carcinoma monoclonal antibody cc49
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
DE19858777B4 (de) * 1998-12-18 2006-07-27 Delta Biotechnology Ltd. Verfahren zur teilweisen oder vollständigen Trennung von glykosilierten und nicht-glykosilierten Proteinen
ATE362912T1 (de) * 1999-12-06 2007-06-15 Leo Pharma As Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
WO2001044472A1 (en) 1999-12-16 2001-06-21 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1370867B1 (en) 2001-03-02 2010-08-04 Activx Biosciences, Inc. Protein profiling platform
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003016909A1 (en) 2001-08-16 2003-02-27 Ludwig Institute For Cancer Research Method for determining protein component in a biological sample
ATE469176T1 (de) 2001-11-12 2010-06-15 Merck Patent Gmbh Modifizierter anti-tnf antikörper
US20060110407A1 (en) 2001-12-05 2006-05-25 Shelley Stopera Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
US20060078944A1 (en) 2002-08-01 2006-04-13 Jun Kuai Methods and reagents relating to inflammation and apoptosis
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
JP4717810B2 (ja) 2003-06-20 2011-07-06 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド １型糖尿病と２型糖尿病を識別するためのバイオマーカー
BRPI0413197A (pt) * 2003-08-01 2006-10-03 Amgen Inc cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
JP2007528868A (ja) 2003-08-14 2007-10-18 ワイス 抗ルイスｙ抗イディオタイプ抗体およびその使用
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
US20060003384A1 (en) 2004-06-30 2006-01-05 Wagner Carrie L Detection of measurement of antibodies to antigenic proteins in biological tissues or samples
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
ZA200709956B (en) 2005-05-20 2009-02-25 Genentech Inc Pretreatment of a biological sample from an autoimmune disease subject
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
WO2007009469A2 (en) 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an fc receptor
US20090162374A1 (en) 2005-09-14 2009-06-25 Geraghty Daniel E Specific removal of activated immune cells
US7542502B2 (en) 2005-09-27 2009-06-02 Cymer, Inc. Thermal-expansion tolerant, preionizer electrode for a gas discharge laser
AU2006311475A1 (en) * 2005-11-08 2007-05-18 Medarex, Inc. TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
JP2007147367A (ja) 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
DE102005057920A1 (de) 2005-12-02 2007-06-28 Strohner, Pavel, Dr. Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben
US20100130367A1 (en) 2006-07-11 2010-05-27 Drexel University Methods of Quantitatively Assessing Inflammation with Biosensing Nanoparticles
US20080286774A1 (en) 2007-05-16 2008-11-20 The Regents Of The University Of California Real-time individualized therapy evaluation
EP2200613B1 (en) * 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
WO2009091240A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
CA2716522A1 (en) 2008-03-05 2009-10-15 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
JP5697677B2 (ja) 2009-10-26 2015-04-08 ネステク ソシエテ アノニム 抗ｔｎｆ薬及び自己抗体の検出用アッセイ
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
CA2827609A1 (en) 2011-02-17 2012-11-15 Nestec S.A. Assays for detecting autoantibodies to anti-tnf.alpha. drugs
US20130266963A1 (en) 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
KR20140047628A (ko) 2011-07-06 2014-04-22 네스텍 소시에테아노님 Ｔｎｆ알파로의 생물학적 치료요법에 대한 중화 자가항체의 검출을 위한 검정
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
US20130295685A1 (en) 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
BR112015012482A2 (pt) 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
CN107250798A (zh) 2014-12-05 2017-10-13 雀巢产品技术援助有限公司 用于检测患者样品中的生物制品的间接均相迁移率变动试验

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ann Rheum Dis., (2007), 66, pp 253-256.
ARTHRITIS & RHEUMATISM, (2006), Vol. 54, No. 12, pp 3782-3789.

Also Published As

Publication number Publication date
CA2778454C (en) 2021-03-02
BR112012009855A2 (pt) 2018-06-26
JP5878253B2 (ja) 2016-03-08
KR20170088437A (ko) 2017-08-01
JP2015148616A (ja) 2015-08-20
MX343328B (es) 2016-11-01
AU2010315547A1 (en) 2012-05-10
RU2015148676A (ru) 2019-01-15
JP2016106222A (ja) 2016-06-16
JP6082831B2 (ja) 2017-02-15
IL219315A0 (en) 2012-06-28
JP2013508739A (ja) 2013-03-07
MX2012004877A (es) 2012-05-23
EP2494352B1 (en) 2020-04-08
US20150024404A1 (en) 2015-01-22
NZ706187A (en) 2016-09-30
CN104634955A (zh) 2015-05-20
RU2012121710A (ru) 2013-12-10
US9506920B2 (en) 2016-11-29
US20120329172A1 (en) 2012-12-27
KR101761541B1 (ko) 2017-07-26
RU2571489C2 (ru) 2015-12-20
AU2017213584A1 (en) 2017-08-31
ZA201504548B (en) 2019-10-30
RU2015148676A3 (https=) 2019-06-18
US8574855B2 (en) 2013-11-05
US20200018751A1 (en) 2020-01-16
AU2010315547B2 (en) 2015-03-05
US20170184588A1 (en) 2017-06-29
IL256728A (en) 2018-04-09
KR20120108978A (ko) 2012-10-05
AU2010315547C1 (en) 2015-06-04
CN104634955B (zh) 2016-09-14
EP2494352A1 (en) 2012-09-05
AU2015202899B2 (en) 2017-06-01
IL219315B (en) 2018-01-31
CA3108458A1 (en) 2011-05-12
WO2011056590A1 (en) 2011-05-12
ZA201203717B (en) 2018-11-28
US8865417B2 (en) 2014-10-21
CN102695955B (zh) 2015-03-18
US20140057367A1 (en) 2014-02-27
AU2017213584B2 (en) 2019-04-18
AU2015202899A1 (en) 2015-06-18
US10386366B2 (en) 2019-08-20
CN102695955A (zh) 2012-09-26
NZ599456A (en) 2014-06-27
ES2796530T3 (es) 2020-11-27
CA2778454A1 (en) 2011-05-12
AU2019205009A1 (en) 2019-08-01
NZ621655A (en) 2015-08-28
JP5697677B2 (ja) 2015-04-08

Similar Documents

Publication Publication Date Title
KR101881714B1 (ko) 항-ｔｎｆ 약물 및 자가항체의 검출을 위한 검정법
CA2815026C (en) Methods for determining anti-drug antibody isotypes
EP2729807B1 (en) Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
US20130295685A1 (en) Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
AU2013350817A1 (en) Assays for detecting neutralizing autoantibodies to biologic therapy
RU2745060C2 (ru) Биомаркеры для комбинированной терапии, включающей ленватиниб и эверолимус
HK1194467B (en) Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Not in force date: 20210719

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210719

St.27 status event code: N-4-6-H10-H13-oth-PC1903